- Home
- THAR vs BPTH Comparison
THAR vs BPTH Comparison
Compare THAR & BPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- BPTH
- Stock Information
- Founded
- THAR 2017
- BPTH 2007
- Country
- THAR United States
- BPTH United States
- Employees
- THAR N/A
- BPTH N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- BPTH Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- BPTH Health Care
- Exchange
- THAR Nasdaq
- BPTH Nasdaq
- Market Cap
- THAR 4.0M
- BPTH N/A
- IPO Year
- THAR 2022
- BPTH N/A
- Fundamental
- Price
- THAR $1.90
- BPTH $0.20
- Analyst Decision
- THAR Strong Buy
- BPTH Strong Buy
- Analyst Count
- THAR 1
- BPTH 2
- Target Price
- THAR $17.00
- BPTH $30.00
- AVG Volume (30 Days)
- THAR 20.9K
- BPTH 867.9K
- Earning Date
- THAR 11-07-2024
- BPTH 03-07-2025
- Dividend Yield
- THAR N/A
- BPTH N/A
- EPS Growth
- THAR N/A
- BPTH N/A
- EPS
- THAR N/A
- BPTH N/A
- Revenue
- THAR N/A
- BPTH N/A
- Revenue This Year
- THAR N/A
- BPTH N/A
- Revenue Next Year
- THAR N/A
- BPTH N/A
- P/E Ratio
- THAR N/A
- BPTH N/A
- Revenue Growth
- THAR N/A
- BPTH N/A
- 52 Week Low
- THAR $1.84
- BPTH $0.20
- 52 Week High
- THAR $7.46
- BPTH $9.80
- Technical
- Relative Strength Index (RSI)
- THAR 43.41
- BPTH 23.36
- Support Level
- THAR $1.86
- BPTH $0.12
- Resistance Level
- THAR $1.95
- BPTH $0.84
- Average True Range (ATR)
- THAR 0.07
- BPTH 0.07
- MACD
- THAR -0.00
- BPTH -0.06
- Stochastic Oscillator
- THAR 16.33
- BPTH 11.11
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.